• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
高级检索

检索历史 清除

氟达拉滨联合吡柔比星治疗复发难治性惰性非霍奇金淋巴瘤

Fludarabine combined with pirarubicin chemotherapy for patients with relapsed or refractory indolent non-Hodgldn lymphoma

摘要:

目的 探讨Fr(氟达拉滨及吡柔比星)方案治疗复发难治惰性非霍奇金淋巴瘤(NHL)的有效性和安全性.方法 复发难治惰性NHL40例,采用FT方案化疗,28 d为1个周期,共6个周期.FND(氟达拉滨、米托蒽醌及地塞米松)方案治疗惰性NHL的数据为对照.结果 FT组40例共治疗228个周期,有效率62.5%,中位无进展生存期超过20个月,2年总生存率70.0%,与对照组相似(P>0.05);不良反应以中性粒细胞减少(80.0%)最为常见,但Ⅲ~Ⅳ度中性粒细胞减少症和肺炎的发生率均低于对照组,分别为12.5%、29.0%和2.5%、23.0%(P<0.05).结论 FT方案治疗复发难治惰性NHL安全有效,骨髓抑制轻,感染发生率低.

更多
abstracts:

Objective To evaluate the efficacy and safety of fludarabine and pirarubicin (FT) regimen in the treatment of refractory or relapsed indolent non-Hodgkin lymphoma (NHL). Methods A total of 40 patients with relapsed or refractory indolent NHL were treated with FT regimen, one cycle for 28 days, total 6 cycles. The data of indolent NHL patients treated with fludarabine, noventrene and dexamethasone (FND) regimen were collected as control. Results 40 patients were given 228 cycles chemotherapy, overall response rate was 62.5 %, median progression-free survival was more than 20 months and 2 years overall survival rate was 70.0 %. The main toxicities was leucopenia (80.0 %), but the incidence of WHO Ⅲ-Ⅳ leucopenia and pneumonia was less than that of in the control group, the rate were 12.5 % vs 29.0 % and 2.5 % vs 23.0 % respectively (P <0.05). Conclusion The efficacy of FT regimen was as good as FND regimen, but the incidence of leucopenia and pneumonia by Ⅲ-Ⅳ was lower in FT group than in FND group. So the FT regimen was an effective and safe second-line salvage regimen for relapsed or refractory indolent non-Hodgkin lymphoma.

More
  • 浏览:293
  • 下载:116

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

充值 订阅 收藏 移动端 使用
帮助